News Releases

August 8, 2019
Synlogic to Present at the 2019 Wedbush PacGrow Healthcare Conference
  CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 8, 2019-- Synlogic, Inc. (NASDAQ: SYBX) announced today that Scott Plevy , M.D., Synlogic’s chief scientific officer, will provide a corporate update at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13 at 9:45 am ET , in New York City ....
August 8, 2019
Synlogic Reports Second Quarter 2019 Financial Results and Provides Program Updates
– Strong balance sheet supports clinical advancement of lead and emerging Synthetic Biotic ™ programs – –Bridging study to evaluate solid oral formulation of SYNB1618 open and recruiting healthy volunteers – – Company will host a conference call and webcast at 5:00 pm ET today – CAMBRIDGE, Mass....
August 1, 2019
Synlogic Announces Second Quarter 2019 Conference Call and Webcast
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2019-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its second quarter 2019 financial results after the market...
July 15, 2019
Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria and Guides to Next Phase of Development
– Data demonstrate statistically significant biomarker activity at well-tolerated dose in PKU patients – – Plan to initiate bridging study with new oral solid formulation in Q3 2019 – – Conference call and webcast today, July 15 , at 8:00 a.m. ET – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul....
June 12, 2019
Synlogic and Ginkgo Bioworks Establish Transformational Platform Collaboration for the Accelerated Development of Novel Synthetic Biotic™ Medicines
– Fuels development of Synlogic’s growing pipeline of novel living medicines with technology access and $80.0 million equity investment at a premium – – Applies Ginkgo’s high-throughput synthetic biology platform services to human therapeutics – – Synlogic to host a conference call at 8:00 am ET...
May 22, 2019
Synlogic Announces Clinical Collaboration to Evaluate SYNB1891 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 22, 2019-- Synlogic, Inc. , (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore Synlogic’s Synthetic...
May 9, 2019
Synlogic Reports First Quarter 2019 Financial Results and Provides Business Update
– Company will host a conference call and webcast at 5:00 pm ET today – CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 9, 2019-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today reported its financial...
May 2, 2019
Synlogic Announces First Quarter 2019 Conference Call and Webcast
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2019-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its first quarter 2019 financial results after the market...
April 30, 2019
Synlogic Presents Data Describing a Solid Oral Formulation Process for Synthetic Biotic™ Medicine SYNB1618 for the Treatment of PKU at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
- Synlogic’s robust and reproducible lyophilization process provides a solid formulation of SYNB1618 with improved quality attributes, stability and minimal loss of viability compared to liquid formulation - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 30, 2019-- Synlogic, Inc....
April 15, 2019
Synlogic to Present Data from New Solid Oral Formulation Process at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 15, 2019-- Synlogic, Inc. , (Nasdaq: SYBX) a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, today announced that data from its program to develop solid oral formulations of...
April 9, 2019
Synlogic Appoints Scott Plevy M.D. as Chief Scientific Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 9, 2019-- Synlogic, Inc . (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Scott Plevy , M.D., as Chief Scientific Officer. Dr....
April 2, 2019
Synlogic to Webcast Presentation at the 18th Annual Needham Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 2, 2019-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the 18th Annual Needham Healthcare Conference at 3:30 pm ET on Tuesday, April 9, 2019 , in...
Displaying 49 - 60 of 136